195 related articles for article (PubMed ID: 22973456)
1. Chemical chaperones improve protein secretion and rescue mutant factor VIII in mice with hemophilia A.
Roth SD; Schüttrumpf J; Milanov P; Abriss D; Ungerer C; Quade-Lyssy P; Simpson JC; Pepperkok R; Seifried E; Tonn T
PLoS One; 2012; 7(9):e44505. PubMed ID: 22973456
[TBL] [Abstract][Full Text] [Related]
2. Bioengineering of coagulation factor VIII for improved secretion.
Miao HZ; Sirachainan N; Palmer L; Kucab P; Cunningham MA; Kaufman RJ; Pipe SW
Blood; 2004 May; 103(9):3412-9. PubMed ID: 14726380
[TBL] [Abstract][Full Text] [Related]
3. Biochemical characterization and immunogenicity of Neureight, a recombinant full-length factor VIII produced by fed-batch process in disposable bioreactors.
Delignat S; Peyron I; El Ghazaly M; V Kaveri S; Rohde J; Mueller F; Lacroix-Desmazes S
Cell Immunol; 2018 Sep; 331():22-29. PubMed ID: 29751951
[TBL] [Abstract][Full Text] [Related]
4. Confocal microscopy analysis of native, full length and B-domain deleted coagulation factor VIII trafficking in mammalian cells.
Becker S; Simpson JC; Pepperkok R; Heinz S; Herder C; Grez M; Seifried E; Tonn T
Thromb Haemost; 2004 Jul; 92(1):23-35. PubMed ID: 15213841
[TBL] [Abstract][Full Text] [Related]
5. Expression and characterization of a codon-optimized blood coagulation factor VIII.
Shestopal SA; Hao JJ; Karnaukhova E; Liang Y; Ovanesov MV; Lin M; Kurasawa JH; Lee TK; Mcvey JH; Sarafanov AG
J Thromb Haemost; 2017 Apr; 15(4):709-720. PubMed ID: 28109042
[TBL] [Abstract][Full Text] [Related]
6. Comparison of factor VIII transgenes bioengineered for improved expression in gene therapy of hemophilia A.
Dooriss KL; Denning G; Gangadharan B; Javazon EH; McCarty DA; Spencer HT; Doering CB
Hum Gene Ther; 2009 May; 20(5):465-78. PubMed ID: 19222367
[TBL] [Abstract][Full Text] [Related]
7. Novel factor VIII variants with a modified furin cleavage site improve the efficacy of gene therapy for hemophilia A.
Nguyen GN; George LA; Siner JI; Davidson RJ; Zander CB; Zheng XL; Arruda VR; Camire RM; Sabatino DE
J Thromb Haemost; 2017 Jan; 15(1):110-121. PubMed ID: 27749002
[TBL] [Abstract][Full Text] [Related]
8. Efficient production of human FVIII in hemophilic mice using lentiviral vectors.
Kootstra NA; Matsumura R; Verma IM
Mol Ther; 2003 May; 7(5 Pt 1):623-31. PubMed ID: 12718905
[TBL] [Abstract][Full Text] [Related]
9. Differential interaction of coagulation factor VIII and factor V with protein chaperones calnexin and calreticulin.
Pipe SW; Morris JA; Shah J; Kaufman RJ
J Biol Chem; 1998 Apr; 273(14):8537-44. PubMed ID: 9525969
[TBL] [Abstract][Full Text] [Related]
10. A novel cause of mild/moderate hemophilia A: mutations scattered in the factor VIII C1 domain reduce factor VIII binding to von Willebrand factor.
Jacquemin M; Lavend'homme R; Benhida A; Vanzieleghem B; d'Oiron R; Lavergne JM; Brackmann HH; Schwaab R; VandenDriessche T; Chuah MK; Hoylaerts M; Gilles JG; Peerlinck K; Vermylen J; Saint-Remy JM
Blood; 2000 Aug; 96(3):958-65. PubMed ID: 10910910
[TBL] [Abstract][Full Text] [Related]
11. Most factor VIII B domain missense mutations are unlikely to be causative mutations for severe hemophilia A: implications for genotyping.
Ogata K; Selvaraj SR; Miao HZ; Pipe SW
J Thromb Haemost; 2011 Jun; 9(6):1183-90. PubMed ID: 21645226
[TBL] [Abstract][Full Text] [Related]
12. Development and characterization of recombinant ovine coagulation factor VIII.
Zakas PM; Gangadharan B; Almeida-Porada G; Porada CD; Spencer HT; Doering CB
PLoS One; 2012; 7(11):e49481. PubMed ID: 23152911
[TBL] [Abstract][Full Text] [Related]
13. Biochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VIII.
Pittman DD; Alderman EM; Tomkinson KN; Wang JH; Giles AR; Kaufman RJ
Blood; 1993 Jun; 81(11):2925-35. PubMed ID: 8499631
[TBL] [Abstract][Full Text] [Related]
14. Efficient adenoviral vector transduction and expression of functional human factor VIII in cultured primary human hepatocytes.
Andrews JL; Weaver L; Kaleko M; Connelly S
Haemophilia; 1999 May; 5(3):160-8. PubMed ID: 10444282
[TBL] [Abstract][Full Text] [Related]
15. Engineered factor IX variants bypass FVIII and correct hemophilia A phenotype in mice.
Milanov P; Ivanciu L; Abriss D; Quade-Lyssy P; Miesbach W; Alesci S; Tonn T; Grez M; Seifried E; Schüttrumpf J
Blood; 2012 Jan; 119(2):602-11. PubMed ID: 22031860
[TBL] [Abstract][Full Text] [Related]
16. A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models.
Stennicke HR; Kjalke M; Karpf DM; Balling KW; Johansen PB; Elm T; Øvlisen K; Möller F; Holmberg HL; Gudme CN; Persson E; Hilden I; Pelzer H; Rahbek-Nielsen H; Jespersgaard C; Bogsnes A; Pedersen AA; Kristensen AK; Peschke B; Kappers W; Rode F; Thim L; Tranholm M; Ezban M; Olsen EH; Bjørn SE
Blood; 2013 Mar; 121(11):2108-16. PubMed ID: 23335368
[TBL] [Abstract][Full Text] [Related]
17. Storage and regulated secretion of factor VIII in blood outgrowth endothelial cells.
van den Biggelaar M; Bouwens EA; Kootstra NA; Hebbel RP; Voorberg J; Mertens K
Haematologica; 2009 May; 94(5):670-8. PubMed ID: 19336741
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanisms of missense mutations that generate ectopic N-glycosylation sites in coagulation factor VIII.
Wei W; Misra S; Cannon MV; Yang R; Zhu X; Gilmore R; Zhu M; Zhang B
Biochem J; 2018 Mar; 475(5):873-886. PubMed ID: 29444815
[TBL] [Abstract][Full Text] [Related]
19. Intracellular trafficking of factor VIII to von Willebrand factor storage granules.
Rosenberg JB; Foster PA; Kaufman RJ; Vokac EA; Moussalli M; Kroner PA; Montgomery RR
J Clin Invest; 1998 Feb; 101(3):613-24. PubMed ID: 9449695
[TBL] [Abstract][Full Text] [Related]
20. Coagulation factors with improved properties for hemophilia gene therapy.
Pipe SW
Semin Thromb Hemost; 2004 Apr; 30(2):227-37. PubMed ID: 15118934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
